These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
302 related articles for article (PubMed ID: 2344169)
1. Beta-lactamase production in members of the family Enterobacteriaceae and resistance to beta-lactam-enzyme inhibitor combinations. Thomson KS; Weber DA; Sanders CC; Sanders WE Antimicrob Agents Chemother; 1990 Apr; 34(4):622-7. PubMed ID: 2344169 [TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate. Fass RJ; Prior RB Antimicrob Agents Chemother; 1989 Aug; 33(8):1268-74. PubMed ID: 2552904 [TBL] [Abstract][Full Text] [Related]
3. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections. Nomura S; Hanaki H; Nagayama A J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745 [TBL] [Abstract][Full Text] [Related]
7. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam. Sader HS; Tosin I; Sejas L; Miranda E Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842 [TBL] [Abstract][Full Text] [Related]
8. Activity of ticarcillin/clavulanate and piperacillin/tazobactam (YTR 830; CL-298,741) against clinical isolates and against mutants derepressed for class I beta-lactamase. Knapp CC; Sierra-Madero J; Washington JA Diagn Microbiol Infect Dis; 1989; 12(6):511-5. PubMed ID: 2560423 [TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam. Kuck NA; Jacobus NV; Petersen PJ; Weiss WJ; Testa RT Antimicrob Agents Chemother; 1989 Nov; 33(11):1964-9. PubMed ID: 2558615 [TBL] [Abstract][Full Text] [Related]
10. Diminished Susceptibility to Cefoperazone/Sulbactam and Piperacillin/Tazobactam in Yang F; Zhao Q; Wang L; Wu J; Jiang L; Sheng L; Zhang L; Xue Z; Yi M Pol J Microbiol; 2022 Jun; 71(2):251-256. PubMed ID: 35716168 [TBL] [Abstract][Full Text] [Related]
11. Susceptibilities of 200 penicillin-susceptible and -resistant pneumococci to piperacillin, piperacillin-tazobactam, ticarcillin, ticarcillin-clavulanate, ampicillin, ampicillin-sulbactam, ceftazidime, and ceftriaxone. Pankuch GA; Jacobs MR; Appelbaum PC Antimicrob Agents Chemother; 1994 Dec; 38(12):2905-7. PubMed ID: 7695281 [TBL] [Abstract][Full Text] [Related]
12. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli. Jacobs MR; Aronoff SC; Johenning S; Shlaes DM; Yamabe S Antimicrob Agents Chemother; 1986 Jun; 29(6):980-5. PubMed ID: 3015017 [TBL] [Abstract][Full Text] [Related]
13. Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830). Eliopoulos GM; Klimm K; Ferraro MJ; Jacoby GA; Moellering RC Diagn Microbiol Infect Dis; 1989; 12(6):481-8. PubMed ID: 2560420 [TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases. Gatermann S; Marre R Infection; 1991; 19(2):106-9. PubMed ID: 1646771 [TBL] [Abstract][Full Text] [Related]
15. Comparative activity of piperacillin/tazobactam against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae. Pagani L; Migliavacca R; Luzzaro F; Giacobone E; Perilli M; Micheletti P; Amicosante G Chemotherapy; 1998; 44(6):377-84. PubMed ID: 9755296 [TBL] [Abstract][Full Text] [Related]
16. Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases. Bonomo RA; Rudin SA; Shlaes DM FEMS Microbiol Lett; 1997 Mar; 148(1):59-62. PubMed ID: 9066111 [TBL] [Abstract][Full Text] [Related]
17. Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases. Akova M; Yang Y; Livermore DM J Antimicrob Chemother; 1990 Feb; 25(2):199-208. PubMed ID: 2158496 [TBL] [Abstract][Full Text] [Related]
18. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate and sulbactam combined with extended-spectrum penicillins against ticarcillin-resistant Enterobacteriaceae and pseudomonads. Jacobs MR; Aronoff SC; Johenning S; Yamabe S J Antimicrob Chemother; 1986 Aug; 18(2):177-84. PubMed ID: 3019984 [TBL] [Abstract][Full Text] [Related]
19. Piperacillin tazobactam compared with co-amoxiclav, ampicillin plus sulbactam and timentin against beta-lactamase-producing clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca. Traub WH; Leonhard B Chemotherapy; 1995; 41(5):345-52. PubMed ID: 8521736 [TBL] [Abstract][Full Text] [Related]
20. Clavulanic acid in combination with ticarcillin: an in-vitro comparison with other beta-lactams. Clarke AM; Zemcov SJ J Antimicrob Chemother; 1984 Feb; 13(2):121-8. PubMed ID: 6323375 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]